About Merus Labs International
Merus Labs International Inc. is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company's products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates. Sintrom is an anticoagulant indicated to treat and prevent thromboembolic diseases. Emselex/Enablex is used in adults to treat overactive bladder syndrome. Surgestone is used to treat women with menstrual irregularities due to ovulation disorder, dysmenorrhea and premenstrual syndrome. Provames is used as hormone replacement therapy in postmenopausal women with symptoms of estrogen deficiency.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Drug Manufacturers - Other
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: MSLI
- Previous Close: $0.86
- 50 Day Moving Average: $0.8274
- 200 Day Moving Average: $0.9309
- 52-Week Range: $0.70 - $1.76
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 28.66
- P/E Growth: 0.0000
- Market Cap: $100.90M
- Outstanding Shares: 117,345,000
- Beta: 1.77
- Net Margins: -10.36%
- Return on Equity: -3.94%
- Return on Assets: -2.20%
Companies Related to Merus Labs International:
- Debt-to-Equity Ratio: 0.55%
- Current Ratio: 0.77%
- Quick Ratio: 0.55%
Earnings History for Merus Labs International (NASDAQ:MSLI)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
Earnings Estimates for Merus Labs International (NASDAQ:MSLI)
Current Year EPS Consensus Estimate: $-0.0400 EPS
Next Year EPS Consensus Estimate: $0.0300 EPS
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Merus Labs International (NASDAQ:MSLI)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading History for Merus Labs International (NASDAQ:MSLI)
No insider trades for this company have been tracked by MarketBeat.com
Latest Headlines for Merus Labs International (NASDAQ:MSLI)
What is Merus Labs International's stock symbol?
Merus Labs International trades on the NASDAQ under the ticker symbol "MSLI."
Where is Merus Labs International's stock going? Where will Merus Labs International's stock price be in 2017?
8 brokers have issued twelve-month price objectives for Merus Labs International's shares. Their forecasts range from $1.00 to $14.00. On average, they anticipate Merus Labs International's stock price to reach $4.15 in the next year.
What are analysts saying about Merus Labs International stock?
Here are some recent quotes from research analysts about Merus Labs International stock:
According to Zacks Investment Research, "Merus Labs International Inc. is a specialty pharmaceutical company engaged in acquisition and licensing of pharmaceutical products. The Company's products include anti-infectives and wound care products. Merus Labs International Inc., formerly known as Envoy Capital Group Inc., is based in Vancouver, Canada. " (2/15/2017)
Canaccord Genuity analysts commented, "We look at MCRB as the leader in advancing the microbiome approach to treating chronic diseases and infections. While we acknowledge that the near-term focus of investors may be how the primary endpoint of reducing the relative risk of infection recurrence in the SER-109 Phase II ECOSPOR clinical study in recurrent Clostridium difficile infection (CDI) was not achieved, we think the stock sell-off since July 29 is overdone. The development of MCRB’s other clinical-stage assets are partnered with Swiss-based Nestle, which has agreed to fund up to one-third of development costs, according to a $1.9B agreement signed in January 2016. MCRB has also signed four other collaborations, which we think represent nascent upside potential in the stock." (8/12/2016)
Who owns Merus Labs International stock?
Merus Labs International's stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Guardian Capital LP (1.01%) and I.G. Investment Management LTD. (0.12%).
Who sold Merus Labs International stock? Who is selling Merus Labs International stock?
Merus Labs International's stock was sold by a variety of institutional investors in the last quarter, including I.G. Investment Management LTD..
How do I buy Merus Labs International stock?
Shares of Merus Labs International can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of Merus Labs International stock cost?
One share of Merus Labs International stock can currently be purchased for approximately $0.86.
Merus Labs International (NASDAQ:MSLI) Chart for Thursday, February, 23, 2017
Institutional Ownership ChartEarnings History ChartDividend History Chart